Table 1.
Patient and treatment characteristics.
| Features | n | Percent |
|---|---|---|
| Gender | ||
| Female | 24 | 50.00 |
| Male | 24 | 50.00 |
| Tumor histology | ||
| Liposarcoma | 9 | 18.75 |
| Synovial sarcoma | 9 | 18.75 |
| Unclassified sarcoma | 9 | 18.75 |
| Leiomyosarcoma | 7 | 14.58 |
| Osteosarcoma | 5 | 10.42 |
| Ewing's sarcoma/primary | 4 | 8.33 |
| neuroectodermal tumor | ||
| Angiosarcoma | 1 | 2.08 |
| Desmoplastic small round cell tumor | 1 | 2.08 |
| Chondrosarcoma | 1 | 2.08 |
| Malignant phyllodes tumor | 1 | 2.08 |
| Rhabdomyosarcoma | 1 | 2.08 |
| Location of primary tumors | ||
| Upper limbs | 4 | 8.33 |
| Lower limbs | 8 | 16.67 |
| Nonextremities | 36 | 75.00 |
| High-grade sarcoma stage | ||
| Early disease with high risk of relapse | 9 | 18.75 |
| Advanced disease | 39 | 81.25 |
| Metastatic at diagnosis | ||
| Yes | 14 | 29.17 |
| No | 34 | 70.83 |
| LVEF assessments at both baseline | ||
| and end of study | ||
| Yes | 38 | 79.17 |
| No | 10 | 20.83 |
| Doxorubicin infusion cycles duration | ||
| 72 hours | 33 | 68.75 |
| 72/48 hours | 15 | 31.25 |